Evidence map›Paper›PMID 27730015›Full record

ArticleIEEE journal of translational engineering in health and medicine2016

The National Institutes of Health Affordable Cancer Technologies Program: Improving Access to Resource-Appropriate Technologies for Cancer Detection, Diagnosis, Monitoring, and Treatment in Low- and Middle-Income Countries.

Paul C Pearlman, Rao Divi, Michael Gwede, Pushpa Tandon, Brian S Sorg, Miguel R Ossandon, Lokesh Agrawal, Vinay Pai, Houston Baker, Tiffani Bailey Lash

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IEEE journal of translational engineering in health and medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Collaborative Paradigm of Preventive, Personalized, and Precision Medicine With Point-of-Care Technologies.IEEE journal of translational engineering in health and medicine · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Paul C PearlmanNational Cancer Institute, National Institutes of Health Department of Health and Human Services Bethesda MD 20892 USA.
Rao DiviNational Cancer Institute, National Institutes of Health Department of Health and Human Services Bethesda MD 20892 USA.
Michael GwedeNational Cancer Institute, National Institutes of Health Department of Health and Human Services Bethesda MD 20892 USA.
Pushpa TandonNational Cancer Institute, National Institutes of Health Department of Health and Human Services Bethesda MD 20892 USA.
Brian S SorgNational Cancer Institute, National Institutes of Health Department of Health and Human Services Bethesda MD 20892 USA.
Miguel R OssandonNational Cancer Institute, National Institutes of Health Department of Health and Human Services Bethesda MD 20892 USA.
Lokesh AgrawalNational Cancer Institute, National Institutes of Health Department of Health and Human Services Bethesda MD 20892 USA.
Vinay PaiNational Institute of Biomedical Imaging and Bioengineering, National Institutes of Health Department of Health and Human Services Bethesda MD 20892 USA.
Houston BakerNational Cancer Institute, National Institutes of Health Department of Health and Human Services Bethesda MD 20892 USA.
Tiffani Bailey LashNational Institute of Biomedical Imaging and Bioengineering, National Institutes of Health Department of Health and Human Services Bethesda MD 20892 USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Point-of-care (POC) technologies have proved valuable in cancer detection, diagnosis, monitoring, and treatment in the developed world, and have shown promise in low-and-middle-income countries (LMIC) as well. Despite this promise, the unique design constraints presented in low-resource settings, coupled with the variety of country-specific regulatory and institutional dynamics, have made it difficult for investigators to translate successful POC cancer interventions to the LMIC markets. In response to this need, the National Cancer Institute has partnered with the National Institute of Biomedical Imaging and Bioengineering to create the National Institutes of Health Affordable Cancer Technologies (ACTs) program. This program seeks to simplify the pathway to market by funding multidisciplinary investigative teams to adapt and validate the existing technologies for cancer detection, diagnosis, and treatment in LMIC settings. The various projects under ACTs range from microfluidic cancer diagnostic tools to novel treatment devices, each geared for successful clinical adaptation to LMIC settings. Via progression through this program, each POC innovation will be uniquely leveraged for successful clinical translation to LMICs in a way not before seen in this arena.

Indexed as

Cancercancer detectioncomputer aided diagnosiscryotherapymedical diagnosis

Identifiers

PMID27730015
PMCPMC5052025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.